Azacitidine, a DNMT inhibitor approved for acute myeloid leukemia (AML), showed encouraging clinical activity in combination with nivolumab for AML patients but limited efficacy with avelumab (ORR = 10.5%) [169,170]. The gene discussed is DNMT1; the disease is acute myeloid leukemia.